Selective Castration-resistant Prostate Cancer Photothermal Ablation With Copper Sulfide Nanoplates - 21/02/19

Résumé |
Objective |
To explore new therapies for castration-resistant prostate cancer to improve patients’ quality of life and extend life.
Materials and Methods |
The synthesis, morphology analysis, phase analysis, spectral analysis, and photothermal conversion test were referenced to our previous articles. Then near-infrared light-driven copper sulfide (CuS) nanoplates to inhibit the growth of prostate cancer cells in vivo and in vitro was carried out. Transmission electron microscope, mCherry-LC3 syncytial virus labeling, acridine orange staining, and autophagy protein were used to detect the autophagy caused by CuS nanoplates and chloroquine was used to inhibit the process of autophagy.
Results |
The CuS nanoplates prepared in this study feature low cytotoxicity, simple preparation, and high photothermal conversion efficiency. Driven by 980 nm near-infrared light, CuS nanoplates could inhibit the growth of prostate cancer cells in vivo and in vitro, while triggering the autophagy and cytoprotection of prostate cancer cells.
Conclusion |
CuS nanoplates are a kind of commendable photothermal therapy agent in castration-resistant prostate cancer treating. Autophagy inhibition enhances the photothermal efficiency of CuS nanoplates, which indicates favorable application prospects in the treatment of advanced prostate cancer.
Le texte complet de cet article est disponible en PDF.Plan
| Funding Support: This work was funded by State Key Laboratory for Modification of Chemical Fibers and Polymer Materials of Donghua University, China (LK1524); National Natural Science Foundation of China (Grant Nos. 51473033, 51773036, 81700590); Science and Technology Commission of Shanghai Municipality for the support under the International Collaboration Project (17410742800); Natural Science Foundation of Shanghai (18ZR1401700). |
|
| Abstract |
Vol 125
P. 248-255 - mars 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
